Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-06-09
2008-05-20
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S412000, C548S241000, C548S469000
Reexamination Certificate
active
07375126
ABSTRACT:
The present invention discloses novel compounds of general formula (I)or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2and Ar1are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
REFERENCES:
patent: 5656634 (1997-08-01), Chang et al.
patent: 6001860 (1999-12-01), Hamanaka
patent: 587180 (1994-03-01), None
patent: 1256574 (2002-11-01), None
patent: WO 98/50347 (1998-11-01), None
patent: WO03014064 (2003-02-01), None
patent: WO 03/055648 (2003-07-01), None
patent: WO03055484 (2003-07-01), None
patent: WO03070247 (2003-08-01), None
patent: WO03080578 (2003-10-01), None
patent: WO03097586 (2003-11-01), None
D. Landsiedel-Maier, “Structure Activity Relationship of Homonchiral 7-Substituted 1-Aminoindans as 5- HTIA Receptor Ligands,”Archiv Der Pharmazie, vol. 331, pp. 59-71, XP002296522 (1998).
J. Sterling, “Novel Dual Inhibitors of AchE and MAO,”Journal of Medicinal Chemistry, vol. 45, No. 24, pp. 5260-5279, XP002296523 (2002).
Prescott,Methods in Cell Biology, Academic Press, New York, N. Y. vol. XIV:33 et seq. (1976).
Berge et al.,J. Pharmaceutical Sciences66:1 et seq. (1977).
IUPAC 1974 Recommendation for Section E, Fundamental Sterochemistry, Pure App. Chem. 45:13-30 (1976).
R.P. Thummel, et al., “Polyaza Cavity-Shaped Molecules. Annelated Derivatives of 2-(2′-Pyridyl)-1,8-naphthyridine and 2,2′-Bi-1,8-naphthyridine”J. Org. Chem., vol. 49, pp. 2208-2212 (1984).
Hayes et al., “Cloning and Functional Expression of a Human Orthologue of Rat Vanilloid Receptor-1”,Pain88:205-215 (2000).
Collier et al., “The Abdominal Constriction Response and its Suppression by Analgesic Drugs in the Mouse,”Br. J. Pharmacol. Chemother. 32:295-310 (1968).
Pircio, et al., “A New Method for the Evaluation of Analgesic Activity using Adjuvant-Induced Arthritis in the Rat”Eur J. Pharmacol. vol. 31(2) pp. 207-215 (1975).
Nolano et al., “Topical Capsaicin in Humans: Parallel Loss of Epidermal Nerve Fibers and Pain Sensation,”Pain81:135-145 (1999).
Caterina et al., “The Vanilloid Receptor: A Molecular Gateway to the Pain Pathway,”Annu. Rev. Neurosci. 24:487-517 (2001).
Caterina et al., “Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin Receptor,”Science288:306-313 (2000).
Caterina et al., “The Capsaicin Receptor: A Heat-Activated Ion Channel in the Pain Pathway,”Nature389:816-824 (Oct. 23, 1997).
Fowler, “Intravesical Treatment of Overactive Bladder,”Urology 55(Supplement 5A) :60-64 (2000).
Davis et al., “Vanilloid Receptor-1 is Essential for Inflammatory Thermal Hyperalgesia,”Nature405:183-186 (2000).
Poste, et al., Prescott (Ed.) Methods in Cell Biology, Academic Press, New York, N.Y. vol. XIV:33 et seq. (1976).
Bayburt Erol K.
Chambournier Gilles
Cink Russell D.
Gomtsyan Arthur R.
Hsu Margaret Chi-Ping
Abbott Laboratories
Davis Zinna N.
Srivastava Sonali S.
LandOfFree
Fused compounds that inhibit vanilloid receptor subtype 1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused compounds that inhibit vanilloid receptor subtype 1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused compounds that inhibit vanilloid receptor subtype 1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3986193